Fluidigm Announces Third Quarter 2020 Financial Results
05 nov. 2020 16h05 HE
|
Fluidigm Corporation
Third Quarter Total Revenue Increased 50 Percent to $39.9 Million Third Quarter Product and Service Revenue Increased 34 Percent to $35.3 Million Driven by COVID-19 Testing GAAP Net Loss in the...
Fluidigm Announces Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
Fluidigm to Present at Upcoming Health Care Investor Conferences
13 mai 2020 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2020 Financial Results
07 mai 2020 16h05 HE
|
Fluidigm Corporation
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for...
Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System
09 déc. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm serving the life science tools market, recognized Fluidigm...
Fluidigm Drives a New Standard in Human Immune Profiling
05 nov. 2019 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced it has exceeded $1 million in revenue from its industry-leading Maxpar® Direct™...
Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
08 janv. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif. and MONTREAL, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing state-of-the-art...
Fluidigm to Participate at Upcoming Investor Events in September
05 sept. 2018 18h00 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s...
Fluidigm Announces Second Quarter 2018 Financial Results
02 août 2018 16h05 HE
|
Fluidigm Corporation
Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE...
Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research
13 avr. 2018 16h10 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Maxpar® Human Immune Monitoring Panel Kit for comprehensive...